Donanemab
A monoclonal antibody targeting amyloid plaques in the brain, specifically the modified N3pG form of amyloid beta, approved for the treatment of early symptomatic Alzheimer's disease. It works by clearing amyloid plaques that are thought to contribute to neurodegeneration in Alzheimer's. Treatment is associated with amyloid-related imaging abnormalities (ARIA), a form of brain swelling or microbleeding that requires MRI monitoring.
Lĩnh vực điều trị
Cơ chế tác dụng
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A monoclonal antibody targeting amyloid plaques in the brain, specifically the modified N3pG form of amyloid beta, approved for the treatment of early symptomatic Alzheimer's disease. It works by clearing amyloid plaques that are thought to contribute to neurodegeneration in Alzheimer's. Treatment is associated with amyloid-related imaging abnormalities (ARIA), a form of brain swelling or microbleeding that requires MRI monitoring.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Donanemab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297245. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="donanemab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/donanemab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/donanemab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/donanemab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="donanemab"></drugfyi-drug>